Evolus, Inc. (NASDAQ:EOLS) Stock Has Consensus Price Target of $14.50

Evolus, Inc. (NASDAQ:EOLS) has earned a consensus recommendation of “Moderate Buy” from the six research firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $14.50.

EOLS has been the topic of several analyst reports. HC Wainwright reiterated a “buy” rating and issued a $13.00 target price on shares of Evolus in a research note on Tuesday, August 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Evolus in a research report on Friday, September 11th. Finally, Wall Street Zen raised shares of Evolus from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th.

Evolus Price Performance

Shares of NASDAQ EOLS opened at $7.36 on Tuesday. The stock has a market capitalization of $486.13 million, a P/E ratio of -14.15 and a beta of 1.33. Evolus has a 1-year low of $3.86 and a 1-year high of $9.31. The business has a fifty day moving average price of $8.15 and a 200 day moving average price of $6.79.

Insiders Place Their Bets

In other Evolus news, insider David Moatazedi sold 105,108 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $9.04, for a total value of $950,176.32. Following the completion of the sale, the insider directly owned 499,592 shares in the company, valued at $4,516,311.68. This trade represents a 17.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 5.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Evolus

A number of large investors have recently made changes to their positions in the business. Nantahala Capital Management LLC purchased a new stake in shares of Evolus during the second quarter worth about $38,878,026. BlackRock Inc. acquired a new position in shares of Evolus during the second quarter valued at about $33,595,000. Braidwell LP increased its holdings in shares of Evolus by 1.6% during the second quarter. Braidwell LP now owns 3,155,209 shares of the company’s stock valued at $21,897,000 after acquiring an additional 50,000 shares in the last quarter. Rice Hall James & Associates LLC acquired a new position in shares of Evolus during the second quarter valued at about $8,952,000. Finally, Assenagon Asset Management S.A. raised its position in shares of Evolus by 51.8% in the 2nd quarter. Assenagon Asset Management S.A. now owns 908,180 shares of the company’s stock valued at $6,303,000 after purchasing an additional 310,035 shares during the last quarter. 90.69% of the stock is owned by institutional investors and hedge funds.

Evolus Company Profile

Evolus, Inc is a commercial-stage medical aesthetics company focused on developing and marketing products for healthcare providers and consumers. The company’s portfolio is designed to address facial wrinkles, folds and other signs of aging through injectable aesthetic treatments.

Evolus’ flagship product is Jeuveau (prabotulinumtoxinA-xvfs), an injectable botulinum toxin approved in the United States for the temporary improvement of moderate to severe glabellar lines in adults. The company markets Jeuveau in the United States and sells the product internationally under the Nuceiva brand in certain markets.

The company has expanded beyond neuromodulators with its Evolysse collection of injectable hyaluronic acid dermal fillers, which is intended to address facial volume loss and wrinkles.